CClinicalTrials.gg
RecruitingNCT07718334Updated Jul 21, 2026

Impact of a Mobile Application-Based Medication Reminder on Treatment Adherence Among Patients With Chronic Diseases and Memory Impairment: A Nursing Leadership Perspective

An interventional study of Mobile Application-Based Medication Reminder in Chronic Disease and Memory Impairment, sponsored by Mansoura University. Recruiting at 2 sites in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Mansoura University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
193
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate the impact of using a mobile application-based medication reminder on medication adherence among patients diagnosed with chronic diseases and memory impairment. Adherence to prescribed therapy is a significant challenge for this patient population, often leading to poor health outcomes and increased healthcare costs. From a nursing leadership perspective, innovative digital solutions can play a crucial role in supporting patient self-management. Using a quasi-experimental design, the study will investigate whether a customized mobile reminder system can effectively improve adherence rates and support patients in managing their therapeutic regimens.

Read the detailed description

Improving medication adherence in patients with chronic illnesses and cognitive decline is a key priority in healthcare management and nursing administration. This quasi-experimental study utilizes a pretest-posttest design to examine the effectiveness of a mobile application-based reminder system designed specifically for patients experiencing memory impairment.

Participants will be selected based on specific inclusion criteria, including being diagnosed with a chronic disease and exhibiting mild-to-moderate memory impairment. Baseline assessments (pretest) will be conducted to measure initial medication adherence levels, patient demographics, and health status. Following the baseline phase, the intervention will be introduced, where participants will utilize the mobile application to receive automated medication alerts and reminders over a specified period. Evaluation (posttest) will be performed post-intervention to analyze changes in adherence rates. The findings are expected to provide insights into how nursing leadership can leverage mobile health (mHealth) technology to design supportive care pathways, enhance patient independence, and reduce clinical complications associated with poor treatment adherence.

02

Conditions studied

  • Chronic Disease
  • Memory Impairment

Keywords

  • medication adherence
  • mobile application
  • medication reminder
  • nursing leadership
  • quasi-experimental study
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients diagnosed with one or more chronic diseases requiring regular long-term medication.
  • Patients exhibiting mild-to-moderate memory impairment or cognitive decline as screened by the Mini-Mental State Examination (MMSE).
  • Patients who personally own and are capable of operating a smartphone or have a primary caregiver willing to manage the mobile application.
  • Patients aged 18 years and older.
  • Patients who provide voluntary informed consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients with severe cognitive impairment or advanced dementia who cannot interact with mobile technology even with caregiver assistance.
  • Patients with severe acute clinical complications or unstable psychiatric conditions.
  • Patients participating in another concurrent clinical trial or study targeting medication adherence
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
193 participants (estimated)

Study arms

  • Experimental
    Mobile Application Group

    Participants in this single-group study will receive training on and utilize a customized mobile application-based medication reminder designed to support adherence to their therapeutic regimens.

    Device: Mobile Application-Based Medication Reminder

Interventions

  • DeviceMobile Application-Based Medication Reminder

    The intervention consists of a mobile application specifically designed to support medication adherence. It features automated push notifications, customized reminder alerts matching prescribed medication schedules, and tracking logs. Participants will be instructed on how to install, configure, and use the application on their personal smartphones. The system is designed to provide immediate prompts to overcome memory-related adherence barriers.

05

What researchers measure

Primary outcomes

  1. Medication Adherence (MMAS-8)

    Medication adherence will be assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8). This self-reported tool evaluates patients' behaviors regarding taking their prescribed chronic medications. Total scores range from 0 to 8, where a score of 8 indicates high adherence, 6 to \<8 indicates medium adherence, and \<6 indicates low adherence.

    Time frame: Baseline (pre-intervention) and 3 months post-intervention

Secondary outcomes

  1. Objective Medication Adherence: Medication Possession Ratio (MPR)

    Medication Possession Ratio (MPR) will be calculated using pharmacy refill records to determine the proportion of time the patient has access to their prescribed medication during the study period. Total scores will range from 0 to 1 (or 0% to 100%), with higher values indicating better adherence.

    Time frame: 3 months post-intervention

  2. Objective Medication Adherence: Proportion of Days Covered (PDC)

    Proportion of Days Covered (PDC) will be assessed using pharmacy refill records to measure the percentage of days the patient covered their prescribed medication dosage over the study duration. Total scores will range from 0 to 1 (or 0% to 100%), where higher values reflect superior medication adherence.

    Time frame: 3 months post-intervention

  3. Cognitive Function Status (MMSE)

    Cognitive impairment levels will be screened using the Mini-Mental State Examination (MMSE) to classify the severity of cognitive/memory impairment among participants.

    Time frame: Baseline

  4. Perceived Nursing Care and Leadership Support

    Evaluated using the Nursing Care and Leadership Support Assessment Tool to measure patient satisfaction and perception of the supportive role played by nursing leadership during the application-based program.

    Time frame: 3 months post-intervention.

06

Study locations

2 of 2 sites recruiting
  • Outpatient Clinics, Delta University for Science and Technology
    Gamasa, Dakahlia Governorate, Egypt
    Recruiting
  • Outpatient Clinics, Kafr El-Sheikh Hospital
    Kafr ash Shaykh, Kafr el-Sheikh Governorate, Egypt
    Recruiting
07

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared to ensure the confidentiality and privacy of the patients' medical records and personal information.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07718334
Lead sponsor
Mansoura University
Collaborators
Al-Azhar University, Delta University for Science and Technology
Responsible party
Asmaa Elwan Mohammed Hassan (Lecturer of Nursing Administration, Faculty of Nursing, Mansoura University, Egypt, Mansoura University) — Principal investigator
First posted
Jul 21, 2026
Start date
May 10, 2026
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Jul 21, 2026

Study contacts

Asmaa Elwan Hassan, PhD
Contact
asmaaelwan@mans.edu.eg
+201063776424
Mona Ahmed Gabr, PhD
Contact
201097898593

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion